Material and Methods
This prospective study was conducted between January and November 2018 in the Obstetrics & Gynecology and Biochemistry Departments of the Harran University Medical Faculty in Sanliurfa, Turkey. This study conformed with the principles of the 2008 Declaration of Helsinki and was approved by the local ethics committee of the Harran University Medical Faculty. Detailed information was provided to all of the women enrolled in this study, and written consent was given by all of the patients.
The study included 23 pregnant women with HM at 7 to 12 weeks of gestation and 24 age and gestational week matched healthy pregnant women. Any individuals with diabetes, thyroid dysfunction or hypertension, multiple gestations, and women whose pathology results were other types of gestational trophoblastic disease, and women who use vitamins or smoke were excluded from the study. The HM diagnosis was made via USG results (Voluson 730 Expert scanner; GE Healthcare, Milwaukee, WI, USA) showing typical complete mole appearance (snowstorm appearance). In addition, patients’ ovaries were evaluated in terms of theca lutein cyst during ultrasonographic examination. In all cases, the preoperative diagnosis of HM was confirmed by postoperative histopathology results.
Each woman’s age, body mass index (BMI), gravidity, parity, blood pressure, thyroid function test, β-hcg level, and urine analysis were documented. The venous blood samples were collected preoperatively when the HM diagnosis was made for the biochemical comparisons between the groups.